T2 Biosystems, Inc. (TTOO) News
Filter TTOO News Items
TTOO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TTOO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TTOO News From Around the Web
Below are the latest news stories about T2 BIOSYSTEMS INC that investors may wish to consider to help them evaluate TTOO as an investment opportunity.
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsAchieved record fourth quarter and full-year 2024 sepsis product revenuesLEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of |
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorMultiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis testsLEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instru |
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyMilestone demonstrates the growing customer adoption of the Company’s proprietary technologyLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company’s direct-from-whole-blood technology. A meta-analysis of |
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bac |
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing PathogensIntends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Bi |
T2 Biosystems Inc (TTOO) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...T2 Biosystems Inc (TTOO) reports a 34% revenue increase, driven by sepsis test sales and a pivotal partnership with Cardinal Health, despite ongoing financial challenges. |
T2 Biosystems: Q3 Earnings SnapshotLEXINGTON, Mass. AP) — T2 Biosystems Inc. TTOO) on Thursday reported a loss of $10.1 million in its third quarter. |
T2 Biosystems Announces Third Quarter 2024 Financial ResultsAchieved 34% quarterly revenue growth compared to the prior year periodLEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compar |
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by |
Q3 2024 T2 Biosystems Inc Earnings CallQ3 2024 T2 Biosystems Inc Earnings Call |